SavyNBrossierDBrunel-GuittonCDucharme-CrevierLDu Pont-ThibodeauGJouvetP.Acute pediatric hyperammonemia: current diagnosis and management strategies. Hepat Med. 2018;10:105-115. doi:10.2147/hmer.S140711.
2.
HäberleJBurlinaAChakrapaniA, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192-1230. doi:10.1002/jimd.12100.
3.
Vasquez-LoarteTThompsonJDMerrittJL2nd.Considering proximal urea cycle disorders in expanded newborn screening. Int J Neonatal Screen. 2020;6(4):77. doi:10.3390/ijns6040077.
4.
OnoHSutoTKinoshitaYSakanoTFurueTOhtaT.A case of carbamoyl phosphate synthetase 1 deficiency presenting symptoms at one month of age. Brain Dev. 2009;31(10):779-781. doi:https://doi.org/10.1016/j.braindev.2008.12.013.
5.
CrombezEACederbaumSD. CHAPTER 110—Urea cycle disorders. In: SchapiraAHVByrneEDimauroS, et al., (eds) Neurology and Clinical Neuroscience. Maryland Heights, MI: Mosby; 2007:1469-1476.
6.
SummarMLDobbelaereDBrusilowSLeeB.Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97(10):1420-1425. doi:10.1111/j.1651-2227.2008.00952.x.
7.
SerranoMMartinsCPérez-DueñasB, et al. Neuropsychiatric manifestations in late-onset urea cycle disorder patients. J Child Neurol. 2010;25(3):352-358. doi:10.1177/0883073809340696.
8.
SedelFBaumannNTurpinJCLyon-CaenOSaudubrayJMCohenD.Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007;30(5):631-641. doi:10.1007/s10545-007-0661-4.
9.
ChoiYOhALeeY, et al. Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency. Clin Chim Acta. 2022;526:55-61. doi:10.1016/j.cca.2021.11.029.
10.
MsallMBatshawMLSussRBrusilowSWMellitsED. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med. 1984;310(23):1500-1505. doi:10.1056/nejm198406073102304.
11.
UchinoTEndoFMatsudaI.Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998;21(Suppl. 1):151-159. doi:10.1023/a:1005374027693.
12.
WaisbrenSEStefanatosAKKokTMYOzturk-HismiB.Neuropsychological attributes of urea cycle disorders: a systematic review of the literature. J Inherit Metab Dis. 2019;42(6):1176-1191. doi:10.1002/jimd.12146.
YapSGougeardNHartARBarcelonaBRubioV.N-carbamoylglutamate-responsive carbamoyl phosphate synthetase 1 (CPS1) deficiency: a patient with a novel CPS1 mutation and an experimental study on the mutation's effects. JIMD Rep. 2019;48(1):36-44. doi:10.1002/jmd2.12034.
15.
Ah MewNMcCarterRDaikhinY, et al. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. J Pediatr. 2014;165(2):401-403. doi:10.1016/j.jpeds.2014.04.012.
FunghiniSThusbergJSpadaM, et al. Carbamoyl phosphate synthetase 1 deficiency in Italy: clinical and genetic findings in a heterogeneous cohort. Gene. 2012;493(2):228-234. doi:10.1016/j.gene.2011.11.052.
18.
Diez-FernandezCHäberleJ.Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder. Expert Opin Ther Targets. 2017;21(4):391-399. doi:10.1080/14728222.2017.1294685.
